Get the Stockscreener App
0.2848
6.87%
0.0183
Pre-market:
.30
0.0152
+5.34%
Genprex Inc stock is traded at $0.2848, with a volume of 1.95M.
It is up +6.87% in the last 24 hours and down -26.24% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$0.2665
Open:
$0.27
24h Volume:
1.95M
Relative Volume:
0.52
Market Cap:
$5.44M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.0243
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
+18.67%
1M Performance:
-26.24%
6M Performance:
-85.62%
1Y Performance:
-86.57%
1-Day Range:
$0.25
$0.29
1-Week Range:
$0.22
$0.29
52-Week Range:
$0.22
$4.0899
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.2848 | 5.44M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma - PR Newswire
Short Interest in Genprex, Inc. (NASDAQ:GNPX) Grows By 487.6% - Defense World
Stock Market Recap: Genprex Inc (GNPX) Concludes at 0.27, a 0.57 Surge/Decline - DWinneX
GNPX’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
Now Is The Time To Build A Position In Genprex Inc (NASDAQ:GNPX) - Marketing Sentinel
Genprex Selected to Present Trial Design of Acclaim-3 Clinical T - GuruFocus
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - PR Newswire
Genprex Inc (GNPX) receives a Buy rating from National Securities - knoxdaily.com
Genprex presents promising gene therapy data for lung cancer By Investing.com - Investing.com South Africa
How Are Things Looking For Genprex Inc (NASDAQ: GNPX) For The Short Term? - Stocksregister
Genprex presents promising gene therapy data for lung cancer - Investing.com
There is no doubt that Genprex Inc (GNPX) ticks all the boxes. - Sete News
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings | GNPX Stock News - GuruFocus
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings - PR Newswire
Ratio Examination: Genprex Inc (GNPX)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Genprex, Inc. (NASDAQ:GNPX) Short Interest Update - Defense World
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer (PR Newswire) - Aktiellt
What Analysts Were Expecting After Genprex Inc (NASDAQ: GNPX) fell -1.73% - stocksregister.com
Analysts Provide Insight Into Genprex Inc’s (GNPX) Potential. - Stocksregister
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Genprex Delays Yearly Report Filing - TipRanks
Genprex Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Genprex, Inc. SEC 10-K Report - TradingView
Genprex (GNPX) Projected to Announce Earnings on Monday - Defense World
Genprex stock plunges to 52-week low of $0.27 By Investing.com - Investing.com South Africa
Genprex stock plunges to 52-week low of $0.27 - Investing.com India
Genprex reports progress in lung cancer gene therapy By Investing.com - Investing.com South Africa
Genprex reports progress in lung cancer gene therapy - Investing.com India
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - Quantisnow
Game-Changing Gene Therapy Could End Daily Insulin Injections for Diabetes Patients - Stock Titan
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® De - GuruFocus.com
Genprex Inc (GNPX) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
Genprex to Participate at BIO Europe Spring 2025 - StreetInsider.com
Genprex to Present at the 2020 LD Micro Virtual Conference - ACCESS Newswire
Genprex Strengthens Diabetes Focus with New License - TipRanks
Genprex explores non-viral gene therapy for diabetes By Investing.com - Investing.com Nigeria
Genprex Advances Diabetes Program With Addition Of Research Focused On Non-Viral Delivery System - Marketscreener.com
Genprex explores non-viral gene therapy for diabetes - Investing.com India
Can This New Delivery System Transform Diabetes Gene Therapy? Genprex's Latest Breakthrough - StockTitan
Genprex advances diabetes gene therapy with new license By Investing.com - Investing.com Nigeria
Genprex Provides Update On Diabetes Gene Therapy Program -February 18, 2025 at 10:03 am EST - Marketscreener.com
Genprex announces advancement of its diabetes gene therapy program - TipRanks
Genprex advances diabetes gene therapy with new license - Investing.com India
Genprex Provides Update on Diabetes Gene Therapy Program - Nasdaq
Genprex faces Nasdaq delisting over stock price, equity issues - MSN
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer - BioSpace
Genprex's New Study Highlights NPRL2 Gene Therapy's Antitumor Activity In Lung Cancer - Nasdaq
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):